Relevance. Achieving remission is one of the main goals in the treatment of patients with rheumatoid arthritis (RA). One of the determining predictors of the disease, according to the literature, is the serological variant of RA. However, there are conflicting data in scientific publications on the relationship between the presence of antibodies to cyclic citrullinated peptide (ACCP) and / or rheumatoid factor (RF) and the frequency and rate of remission. There is no unanimous opinion in the literature on the influence of the titer of serological markers of RA (ACCP and RF) on the possibility of achieving remission on the background of basic treatment, which prompted to conduct their own research to study this issue. Objective: to study the relationship between the presence / absence of serological markers of RA (ACCP, RF) and the frequency and timing of clinical and radiological remission of RA under the influence of treatment with traditional synthetic basic drugs and to analyze the relationship between ACCP and RF titers and the possibility of remission.Material and methods. The study analyzed the influence of serological status of patients with RA on the possibility and time of remission while taking the main non-biological basic drugs. The relationship between the presence and level of ACCP and / or RF and clinical and radiological remission in RA has been studied. The study included 128 patients. Analysis of RA activity and assessment of remission were performed after 6, 12 and 24 months of treatment, using the DAS28 activity scale and the dynamics of radiological changes on the Sharpe-van der Heide scale.
Results. During the 2-year follow-up, clinical remission was observed three times more often in the group of patients negative for ACCP (anti-cyclic citrullinated peptide) (36.1% in the group ACCP-RF- compared with 12.5% in the group ACCP + RF ( +, χ2 = 7.74, p < 0.05, and in 33.3% in the group ACCP-RF +, a significant difference compared with ACCP + RF +, χ2 = 4.55, p <0.05). Early remission (during the first 6 months of treatment) was also more common in the group of patients with no ACCP (χ2 = 10.7, p <0.01 and χ2 = 6.69, p <0.05, respectively). The rate of remission (the share of early in the structure of the total) in the four analyzed groups did not differ significantly and was 75%, 66.6%, 66.6% and 84.6%, respectively. The titer of ACCP in the group of patients who achieved remission was 240.8 ± 38.5 and did not differ significantly from that in the group of patients whose RA (rheumatoid arthritis) activity exceeded the remission threshold (187.8 ± 13.7, p> 0.05). There was also no significant difference between these two groups in the titers of the RF (rheumatoid factor): 257.9 ± 233.8 and 293.2 ± 257.3, respectively. Radiological remission was achieved in 46.7% of ACCP-negative patients and only in 10.6% of ACCP-positive patients (p <0.01). The absence of RF in the blood was also associated with a more frequent achievement of radiological remission (in 34.2% of patients) compared with the RF-positive cohort of patients (in 15.4%, p <0.05).
Conclusions. It was found that the frequency of clinical remission, including early (during the first 6 months of treatment), is three times higher in patients with RA, negative for ACCP. The rate of clinical remission (ratio of early in the structure of the general) does not depend on the serological variant of the disease: about two thirds of patients in all analyzed groups achieve remission in the first half of basic therapy. Titers of the main serological markers of RA (ACCP and RF) in the onset of the disease do not affect the possibility of achieving clinical and radiological remission. Radiological remission is observed three times more often in seronegative (for ACCP or RF) patients. Double seropositivity has an additive effect on subsequent joint destruction.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, Vollenhoven RF, Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update FREE. Ann Rheum Dis. 2019;79(6):685-99. DOI: 10.1136/annrheumdis-2019-216655
Publisher site: https://ard.bmj.com/content/79/6/685
Yu C, Jin S, Wang Y, Jiang N, Wu C , Wang Q, Tian X, Li M, Zeng X . Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clinical Rheumatology. 2019;38(3):727-738. DOI: 10.1007/s10067-018-4340-7.
Europe PMC https://europepmc.org/article/med/30341703
Miriovsky BJ, Michaud K, Thiele GM, O'Dell JR, Cannon GW, Kerr G, Richards JS, Johnson D, Caplan L, Reimold A, Hooker R, Mikuls TR. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1292-1297. DOI: 10.1136/ard.2009.122739
Publisher site: https://ard.bmj.com/content/69/7/1292
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122886/
Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, Vollenhoven RF. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis. 2005;64:1744-1749. DOI: 10.1136/ard.2004.033571
Publisher site: https://ard.bmj.com/content/64/12/1744
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1755292/
Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004;63:1085-1089. DOI: 10.1136/ard.2003.016808.
Publisher site: https://ard.bmj.com/content/63/9/1085
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1755123/
Visser K., Verpoort KN., van Dongen H, Kooij SM, Allaart CF, Toes REM, Huizinga TWJ, van der Helm-van Mil AHM. Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis. 2008;67:1194-1195. DOI: 10.1136/ard.2008.088070
Publisher site: https://ard.bmj.com/content/67/8/1194
Yilmaz-Oner S, Gazel U, Can M, Atagunduz P, Direskeneli H, Inanc N. Predictors and the optimal duration of sustained remission in rheumatoid arthritis. Clin Rheumatol. 2019;38(11):3033-3039. DOI: 10.1007/s10067-019-04654-7.
Jadhav PP, Avhad JD, Mahajan M, Patel AM, Gavli HR, Jadhav JP, Khandelwal V. Dual antibody status predicts sustained remission in patients with rheumatoid arthritis. Indian J Rheumatol. 2019;14:32-36. DOI: 10.4103/injr.injr_107_18.
Choe JY, Bae J, Lee H, Bae SC, Kim SK. Relation of rheumatoid faсtor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study. Rheumatol Int. 2013;33(9):2373-2379. DOI: 10.1007/s00296-013-2734-z.
Wevers-de Boer K, Visser K, Heimans L, Ronday HK, Molenaar E, Groenendael JHLM, Peeters AJ, Westedt ML, Collée G, Sonnaville PBJ, Grillet BAM, Huizinga TWJ, Allaart CF. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis. 2012;71:1472-1477. DOI:10.1136/annrheumdis-2011-200736.
Publisher site: https://ard.bmj.com/content/71/9/1472
Europe PMC: https://europepmc.org/article/med/22402145
Fedele AL, Gremese E, Bosello SL, Cianci F, Carbonella A, Gigante MR, Canestri S., Tolusso B., Ferraccioli G. Disease Characteristics, Treatment Response and Remission in A Prospective Early Rheumatoid Arthritis Cohort: Does Autoantibody Seropositivity Matter? Annals of the Rheumatic Diseases. 2014;73(Suppl 2):262-262. DOI:10.1136/annrheumdis-2014-eular.4294.
Publisher site: https://ard.bmj.com/content/73/Suppl_2/262.1
Sokka T, Kyburz D, Rannio T, Antic M. Difficult cases: Seronegative rheumatoid arthritis. Аnn Rheum Dis.2013;71:4. DOI:10.1136/annrheumdis-2012-eular.1486.
Publisher site: https://ard.bmj.com/content/71/Suppl_3/4.2
Dongen H, Aken J, Lard LR,Visser K, Ronday HK, Hulsmans HM, Speyer I, Westedt ML, Peeters AJ, Allaart CF, Toes RE, Breedveld FC, Huizinga TW. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007; 56(5):1424-1432. DOI: 10.1002/art.22525.
Publisher site: https://onlinelibrary.wiley.com/doi/full/10.1002/art.22525
Pope JE, Movahedi M, Rampakakis E,Cesta A, Sampalis JS, Keystone E, Thorne C, Bombardier C. ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI). RMD Open. 2018;4(2):e000738. DOI:10.1136/ rmdopen-2018-000738
Publisher site: https://rmdopen.bmj.com/content/4/2/e000738
Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):196-201. DOI: 10.1136/ard.2003.019992.
Publisher site: https://ard.bmj.com/content/64/2/196
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1755350/
Takeuchi T, Miyasaka N, Inui T, Yano T, Yoshinari T, Abe T, Koike T. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Arthritis Res Ther. 2017; 19: 194. DOI: 10.1186/s13075-017-1401-2
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581496/
Gardette A, Ottaviani S, Tubach F, Roy C, Nicaise-Roland P, Palazzo E, GGill, Meyer O, Dieudé P. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine. 2014;81(5):416-420. DOI: 10.1016/j.jbspin.2014.06.001.
Hetland ML, Østergaard M, Stengaard-Pedersen K, Junker P., Ejbjerg B, Jacobsen S, Ellingsen T, Lindegaard H, Pødenphant J, Vestergaard A, Jurik AG, Krogh NS, Hørslev-Petersen K, and the CIMESTRA study group. Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis. Scand J Rheumatol. 2019;48(1):1-8. DOI: 10.1080/03009742.2018.1466362.
Quintana-Duque MA, Rondon-Herrera F, Mantilla RD, Calvo-Paramo E, Yunis JJ, Varela-Nariño A, Restrepo JF, Iglesias-Gamarra A. Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study. Clin Rheumatol. 2016;35(6):1463-73. DOI: 10.1007/s10067-016-3246-5.
Europe PMC: https://europepmc.org/article/med/27041382
Hetland ML, Stengaard-Pedersen K, Junker P, Ostergaard M, Ejbjerg BJ, Jacobsen S, Lottenburger T, Hansen I, Tarp U, Andersen LS, Svendsen A. Pedersen JK, Lauridsen UB, Ellingsen T, Lindegaard H, Podenphant J, Vestergaard A, Jurik AG, Horslev-Petersen K. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis. 2010;69(10):1789-1795. DOI: 10.1136/ard.2009.125534.
Publisher site: https://ard.bmj.com/content/69/10/1789
Castrejón I, Dougados M, Combe B, Fautrel B, Guillemin F, Pincus T. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. J Rheumatol. 2016;43(7):1285-91. DOI: 10.3899/jrheum.141586.
Publisher site: https://www.jrheum.org/content/43/7/1285
Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018 Nov 16;4(2):e000752. DOI: 10.1136/rmdopen-2018-000752. eCollection 2018.
Publisher site: https://rmdopen.bmj.com/content/4/2/e000752
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.1988; 31(3): 315-324. DOI: https://doi.org/10.1002/art.1780310302.
Publisher site: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780310302
Gestel AM, Prevoo MLL., van’t Hof MA, Putte LB, Riel PL. Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum. 1996; 39(1):34-40. DOI: 10.1002/art.1780390105.
Publisher site: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780390105
van der Heijde D.M. How to read radiographs according to the Sharp/van der Heijde method. J. Rheumatol.2000; 27(1):261-263.
Jäntti J, Kaarela K, Kautiainen H, Isomäki H, Aho K. Radiographic remission in seropositive rheumatoid arthritis. A 20-year follow-up study. Clin Exp Rheumatol. 2001;19(5):573-576.
Iaremenko OB, Mikitenko GM. [Clinical and laboratory characteristics of rheumatoid art depending on the presence of antibodies to cyclic citrulline peptide]. Ukranian rheumatological magazine. 2008;4:51-55. [in Ukranian]
Iaremenko O, Mykytenko G, Fedkov D. [Effect of the main non-biological disease modifying antirheumatic drugs on radiographic progression in patients with different duration of rheumatoid arthritis]. Journal of International Scientific Publications: Materials, Methods and Technologies. 2013;7(Pt 2): 421-431.
Ratnik K, Baranauskaite A, Iancuta I, Vlak T. Data on the Impact of Anti-Cyclic-Citrulinnated Peptide Antibody Status (ANTI-CCP) on the Management of Patients with Early Rheumatoid Arthritis. Ann Rheum Dis. 2014;73(Suppl 2): 884-884. DOI: 10.1136/annrheumdis-2014-eular.3845
Punder YD, Hendrikx J, Pascual VE, van Riel P., Fransen J. The relationship between inflammation and joint damage in rheumatoid arthritis is dependent on anti-CCP status. Ann Rheum Dis. 2014;71(Suppl 3):510-511. DOI:10.1136/annrheumdis-2012-eular.3066
Publisher site: https://ard.bmj.com/content/71/Suppl_3/510.2
Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, Keystone EC, Thorne JC, Tin D, Bykerk VP. and the CATCH Investigators. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. The Journal of Rheumatology. 2014;41(12):2361-2369. DOI: https://doi.org/10.3899/jrheum.140082
Publisher site: https://www.jrheum.org/content/41/12/2361
van der Helm-van Mil A.H., Verpoort KN, Breedveld FC, Toes REM, Huizinga TWJ. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7(5):R949-958. DOI: 10.1186/ar1767
Chung SW, Choi JY, Lee SH. Predicting Imaging Remission in Rheumatoid Arthritis: a Case-control Ultrasound Study. J Korean Med Sci. 2020; 35(31): e260. DOI: 10.3346/jkms.2020.35.e260
Publisher site: https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e260
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416004/
Katchamart W, Koolvisoot A, Aromdee, Chiowchanwesawakit P, Muengchan C. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol. Int. 2015; 35(10): 1693-1699. DOI: 10.1007/s00296-015-3271-8
Park Eun-Jung, Jeong WooSeong, Kim Jinseok. Prognostic Factors for Radiographic Progression in Patients with Seronegative Rheumatoid Arthritis. Journal of Personalized Medicine. 2021; 11(3): 184. DOI: 10.3390/jpm11030184
Publisher site: https://www.mdpi.com/2075-4426/11/3/184
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001159/
Hecht C, Englbrecht M, Rech J, Schmidt S , Araujo E, Engelke K, Finzel S, Schett G. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis. 2015;74:2151-6. DOI:10.1136/annrheumdis-2014-205428
Publisher site: https://ard.bmj.com/content/74/12/2151
This work is licensed under a Creative Commons Attribution 4.0 International License.